In Focus
As pharmaceutical companies increasingly explore subcutaneous alternatives to intravenous treatments, Swedish pharmaceutical company Camurus has built its business around what happens after an injection – and how a drug can be released slowly beneath the skin. Its pipeline includes both new and established active substances combined with its FluidCrystal technology, with the aim of extending the time between injections and improving treatment outcomes.
Beyond the injection: How Camurus is developing longer-acting medicines
Camurus specialises in long-acting medicines designed to extend the time between injections. As the drug delivery landscape changes, the company believes its technology gives it a distinct position and a window of opportunity in the market. This is the third part of a Life Science Focus series exploring the shift towards subcutaneous drug administration.
Advertisement
BREAKING